News & Press

News & Press

Recognition, research, and stories from CureRays Radiation Medicine® and the CureRays Institute.

On this page

News Articles

  • Jan 10, 2025 — CureRays offers rays of hope for cancer patients in remission: Survivorship Clinic meant to guide people through their next steps
  • Nov 20, 2024 — Doc Talk with Sandra Barrington
  • Feb 26, 2024 — Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
  • Apr 5, 2023 — Doc Talk with Sandra Barrington
  • Apr 3, 2023 — KNCO News Talk Radio Guesting
  • Feb 28, 2023Writing the next chapter: Living well following cancer
  • Nov 8, 2022 — Screening Offers Best Tool in Fight Against Lung Cancer
  • Oct 18, 2022 — Sheriff Shares Personal Journey: Breast Cancer Diagnosis Reaffirms Her Belief in Community
  • Sep 6, 2022 — Living longer — part man, part machine
  • Aug 24, 2022 — Seed hardening — sow struggle to harvest hope
  • Aug 11, 2022 — Smoker? A scan today keeps cancer away
  • Aug 8, 2022 — Fragile heartbeats — handle with care
  • Aug 4, 2022 — Happy screening, happy life (saving)
  • Aug 1, 2022 — “Linac” — a photon flashlight to fight cancer
  • Jul 28, 2022 — The Cause or Merely a Coincidence?
  • Jul 13, 2022Breathe: Your DNA is like LEGOs made from sugar
  • May 31, 2022 — ‘A Window into the Body’: New Tool Available Locally for Fight Against Head and Neck Cancers
  • Sep 2, 2020 — Sierra Nevada Memorial Hospital (SNMH) welcomes Clayton Hess, MD, MPH

Recognition & research highlights

Excellence in Action

Recognized by Sierra Nevada Memorial Hospital as innovative practice of the year.

Best of ASTRO

Research designation for a Phase III trial of whole-lung low-dose radiation (LDRT) in COVID-19-related pneumonia.

Global health

ARRO/ASTRO Global Health Scholarship funding work to improve cervical-cancer treatment in rural Brazil.

IG-SRT first-line

A 2025 expert panel affirmed image-guided superficial radiation as a safe, effective first-line option for selected non-melanoma skin cancers.

Media & inquiries

For press inquiries, interviews, or to learn more about our research and outcomes, please reach out to our team. Follow our social channels for the latest updates.

Get in touch

Contact us for press, partnership, or research inquiries.

Contact us